July 2023

Le tofacitinib réduit l'inflammation spinale dans les corps vertébraux et les éléments postéro-latéraux dans la spondylarthrite ankylosante : Résultats d'un essai de phase 2

Rheumatol Ther. 2023;10(4):1001–1020 doi 10.1007/s40744-023-00564-y

Tofacitinib treatment is associated with a significant improvement in CANDEN MRI scores of spinal inflammation in axSpA patients. This study by Østergaard, et al. also validates the CANDEN MRI scoring system as an approach for measuring axSpA-associated inflammatory lesions.

Keywords:

June 2023

Two‑Year Imaging Outcomes from a Phase 3 Randomized Trial of Secukinumab in Patients with Non‑Radiographic Axial Spondyloarthritis

Arthritis Res Ther. 2023;16;25(1):80 doi 10.1186/s13075-023-03051-5

Braun et al. studied a large cohort of patients with nr-axSpA, that demonstrated a secukinumab reduced SI joint inflammation (BME), this reduction was sustained over 104 weeks, from an overall low baseline level of spinal inflammation or structural damage.

Keywords:

December 2022

Mise en œuvre du système de notation OMERACT pour l'imagerie par résonance magnétique du rhumatisme psoriasique dans une étude randomisée de phase IIb de l'abatacept dans le rhumatisme psoriasique

Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac073

In this study abatacept 30/10 mg/kg and 10 mg/kg doses were associated with greater improvements from baseline in MRI detected synovitis and tenosynovitis, respectively, compared with placebo, confirming the clinical outcomes. Indeed, inflammatory components demonstrated the greatest change from baseline.

Keywords:

August 2022

Efficacité et sécurité du sécukinumab chez les patients atteints de spondylarthrite et d'enthésite du tendon d'Achille : résultats d'un essai de phase 3b

Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keab784

Secukinumab improves the burden of heel enthesitis as assessed by patient and physician reported outcomes in patients with active SpA refractory to standard treatment. In coming to this conclusion, the ACHILLES trial aimed to demonstrate the efficacy of secukinumab on Achilles’ tendon enthesitis in SpA patients.

Keywords:

July 2022

Facteurs associés à la rémission sans médicament à 5 ans chez les patients atteints de spondylarthrite axiale récente : Données de la cohorte DESIR

Joint Bone Spine. 2022 doi.org/10.1016/j.jbspin.2022.105358

This study from Ruyssen-Witrand et al, highlights that the probability of being in drug free remission at 5-year in patients with recent onset of axSpA is low. The study was performed to investigate the possible association between demographic, clinical, biological and imaging characteristics and drug-free remission at 5 years.

Keywords:

June 2022

Le filgotinib diminue l'inflammation du corps vertébral et de la colonne postéro-latérale dans la spondylarthrite ankylosante : Résultats de l'essai TORTUGA

Rheumatology 2022;61:2388–2397. doi: 10.1093/rheumatology/keab758

Maksymowych et al., assessed the effects of filgotinib on inflammatory and structural changes at various spinal locations, based on MRI measures in patients with active ankylosing spondylitis in the TORTUGA trial. Correlations between changes in the inflammation score and clinical outcomes were also evaluated.

Keywords:

Caractéristiques de l'imagerie par résonance magnétique chez les patients atteints de spondylarthrite avec diagnostic clinique d'enthésite du talon : analyse post hoc de l'essai de phase 3 ACHILLES

Arthritis Res Ther. 2022 doi: 10.1186/s13075-022-02797-8

Enthesitis is a hallmark feature of SpA, including PsA and axSpA, and is proposed as the primary lesion in spondyloarthropathies. This study aimed to investigate the imaging characteristics of heel enthesitis in SpA in a post hoc analysis using the HEMRIS in blinded and centrally read MRI data from the ACHILLES trial..

Keywords:

Ixekizumab dans la spondyloarthrite axiale radiographique avec et sans protéine C-réactive élevée ou imagerie par résonance magnétique positive

Rheumatology Expert, 2022 DOI: 10.1093/rheumatology/keac104

Maksymowych et al., evaluated the efficacy of Ixekizumab in patients with radiographic axial spondyloarthritis (r-axSpA) with and without objective measures of inflammation.

Keywords:

Impact du filgotinib sur les lésions structurelles de l'articulation sacro-iliaque obtenues par imagerie par résonance magnétique à 12 semaines chez les patients atteints de spondylarthrite ankylosante active (essai TORTUGA)

Rheumatology 2022;61:2063–71 doi:10.1093/rheumatology/keab543

Maksymowych et al., carried out a post-hoc analysis to assess the effect of filgotinib on MRI measures of structural change in the SI joint in patients with active AS in the TORTUGA trial. This study evaluated lesions using SPARCC SSS definitions for erosion, backfill, fat metaplasia and ankylosis by two independent scoring readers.

Keywords: